Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure

References

• Ponikowski P1, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;27:2129–2200.
   Web of Science ®Google Scholar
• Filippatos G, Khan SS, Ambrosy AP, et al. International REgistry to assess medical practice with longitudinal observation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015;17(5):527–533. doi:10.1002/ejhf.26225754836
   PubMed Web of Science ®Google Scholar
• Jhund PS. Obesity and heart failure: when ‘epidemics’ collide. Eur Heart J. 2017;38(24):1934–1936. doi:10.1093/eurheartj/ehw35728369264
   PubMed Web of Science ®Google Scholar
• Ferrari R, Böhm M, Cleland JGF, et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail. 2015;17(7):665–671. doi:10.1002/ejhf.30426079097
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox în heart failure. Prog Cardiovasc Dis. 2018;61(2):151–156. doi:10.1016/j.pcad.2018.05.00529852198
   PubMed Web of Science ®Google Scholar
• Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 2017;92(2):266–279. doi:10.1016/j.mayocp.2016.11.00128109619
   PubMed Web of Science ®Google Scholar
• Montero D, Flammer AJ. Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy? Eur J Heart Fail. 2017;19(8):971–973. doi:10.1002/ejhf.81128370920
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373e83. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Formiga F, Moreno-Gonzalez R, Chivite D, et al. High comorbidity, measured by the charlson comorbidity index, associates with higher 1-year mortality risks in elderly patients experiencing a first acute heart failure hospitalization. Aging Clin Exp Res. 2017;30(8):927–933. doi:10.1007/s40520-017-0853-129124524
   PubMed Web of Science ®Google Scholar
• Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017;38(25):1951–1958. doi:10.1093/eurheartj/ehx18128873951
   PubMed Web of Science ®Google Scholar
• Padwal R, McAlister F, McMurray JJ, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes. 2014;38(8):1110–1114. doi:10.1038/ijo.2013.203
   PubMed Web of Science ®Google Scholar
• Yumuk V1, Tsigos C, Fried M, et al. Obesity management task force of the european association for the study of obesity. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424. doi:10.1159/00044272126641646
   PubMed Web of Science ®Google Scholar
• Peralta M, Ramos M, Lipert A, Martins J, Marques A. Prevalence and trends of overweight and obesity in older adults from 10 European countries from 2005 to 2013. Scand J Public Health. 2018;46(5):522–529. doi:10.1177/140349481876481029569525
   PubMed Web of Science ®Google Scholar
• Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611–617. doi:10.1016/j.ijcard.2014.08.00725156856
   PubMed Web of Science ®Google Scholar
• Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care. 2014;37(11):2899–2908. doi:10.2337/dc14-066925342830
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Card Fail. 2017;23(8):628–651. doi:10.1016/j.cardfail.2017.04.01428461259
   PubMed Web of Science ®Google Scholar
• Lourenço AP, Leite-Moreira AF, Balligand JL, et al. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the working group on myocardial function of the European society of cardiology. Eur J Heart Fail. 2018;20(2):216–227. doi:10.1002/ejhf.105929148148
   PubMed Web of Science ®Google Scholar
• Clarke B, Howlett J, Sapp J, et al. The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. Can J Cardiol. 2011;27(2):254e61. doi:10.1016/j.cjca.2010.12.05321459274
   PubMed Web of Science ®Google Scholar
• Richards AM. The relationship of plasma NT-proBNP to age and outcomes in heart failure. JACC Heart Fail. 2016;4(9):746–748. doi:10.1016/j.jchf.2016.06.00627522629
   PubMed Web of Science ®Google Scholar
• Srisawasdi P, Vanavanan S, Charoenpanichkit C, et al. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 2010;133(1):14–23. doi:10.1309/AJCP60HTPGIGFCNK20023254
   PubMed Web of Science ®Google Scholar
• Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44(3):303–308. doi:10.1111/eci.1223424372567
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Krum H. Heart failure in diabetes: effects of antihyperglycaemic drug therapy. Lancet. 2015;385(9982):2107–2117. doi:10.1016/S0140-6736(14)61402-126009231
   PubMed Web of Science ®Google Scholar
• Saeed A, Ballantyne CM. Assessing cardiovascular risk and testing in type 2 diabetes. Curr Cardiol Rep. 2017;3(3):19. doi:10.1007/s11886-017-0831-4
   Web of Science ®Google Scholar
• Peng Q, Hu W, Su H, et al. Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus. Exp Ther Med. 2013;5(1):229–232. doi:10.3892/etm.2012.76023251273
   PubMed Web of Science ®Google Scholar
• Clodi M, Resl M, Neuhold S, et al. A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol. 2012;19(5):944–951. doi:10.1177/174182671142001521856715
   PubMed Web of Science ®Google Scholar
• Wang HJ, Si QJ, Shan ZL, et al. Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience. PLoS One. 2015;10(4):e0123516. doi:10.1371/journal.pone.012351625848965
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–1678.27567465
   PubMed Web of Science ®Google Scholar
• Lavie CJ, De Schutter A, Parto P, et al. Obesity and prevalence of cardiovascular diseases and prognosis-the obesity paradox updated. Prog Cardiovasc Dis. 2016;58(5):537–547. doi:10.1016/j.pcad.2016.01.00826826295
   PubMed Web of Science ®Google Scholar
• Yagawa M1, Nagatomo Y, Izumi Y, et al. Effect of obesity on the prognostic impact of atrial fibrillation in heart failure with preserved ejection fraction. Circ J. 2017;81(7):966–973. doi:10.1253/circj.CJ-16-113028367843
   PubMed Web of Science ®Google Scholar
• Knudsen CW, Omland T, Clopton P, et al. A. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005;46(5):838–844. doi:10.1016/j.jacc.2005.05.05716139134
   PubMed Web of Science ®Google Scholar
• Zheng LH, Wu LM, Yao Y, et al. Impact of body mass index on plasma N-terminal ProB-type natriuretic peptides in Chinese atrial fibrillation patients without heart failure. PLoS One. 2014;9(8):e105249. doi:10.1371/journal.pone.010524925144363
   PubMed Web of Science ®Google Scholar
• López J, Cortés-Bergoderi M. Update: systemic diseases and the cardiovascular system (i): obesity and the heart. Rev Esp Cardiol. 2011;64(2):140–149. doi:10.1016/j.recesp.2010.10.01021277668
   PubMed Web of Science ®Google Scholar
• Sandhu RK, Ezekowitz J, Andersson U, et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. Eur Heart J. 2016;37(38):2869–2878. doi:10.1093/eurheartj/ehw12427071819
   PubMed Web of Science ®Google Scholar